▶ 調査レポート

世界のファーマコゲノミクス(PGX)市場規模・現状・予測(2021年-2027年)

• 英文タイトル:Global Pharmacogenomics (PGx) Market Size, Status and Forecast 2021-2027

QYResearchが調査・発行した産業分析レポートです。世界のファーマコゲノミクス(PGX)市場規模・現状・予測(2021年-2027年) / Global Pharmacogenomics (PGx) Market Size, Status and Forecast 2021-2027 / QFJ1-3595資料のイメージです。• レポートコード:QFJ1-3595
• 出版社/出版日:QYResearch / 2021年6月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、120ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:産業装置
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査レポートでは、ファーマコゲノミクス(PGX)の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(ポリメラーゼ連鎖反応(PCR)、マイクロアレイ、シーケンシング、その他)、用途別市場規模(心血管疾患(CVD)、中枢神経系(CNS)、癌/腫瘍、感染症、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・ファーマコゲノミクス(PGX)の市場動向
・企業の競争状況、市場シェア
・ファーマコゲノミクス(PGX)の種類別市場規模と予測2016-2027(ポリメラーゼ連鎖反応(PCR)、マイクロアレイ、シーケンシング、その他)
・ファーマコゲノミクス(PGX)の用途別市場規模と予測2016-2027(心血管疾患(CVD)、中枢神経系(CNS)、癌/腫瘍、感染症、その他)
・ファーマコゲノミクス(PGX)の北米市場規模2016-2027(アメリカ、カナダ)
・ファーマコゲノミクス(PGX)の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・ファーマコゲノミクス(PGX)のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・ファーマコゲノミクス(PGX)の中南米市場規模2016-2027(メキシコ、ブラジル)
・ファーマコゲノミクス(PGX)の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Abbott Laboratories、Affymetrix, Inc.、Assurex Health, Inc、Astrazeneca、GeneDX、Illumina, Inc.、Laboratory Corporation of America Holdings、Myriad Genetics, Inc.、Pathway Genomics、Pfizer, Inc、Qiagen, Inc.、Rocheg、Teva Pharmaceutical Industries Ltd.、Thermo Fisher Scientific、Transgenomic, Inc.)
・結論

Market Analysis and Insights: Global Pharmacogenomics (PGx) Market
The global Pharmacogenomics (PGx) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pharmacogenomics (PGx) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pharmacogenomics (PGx) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pharmacogenomics (PGx) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pharmacogenomics (PGx) market.

Global Pharmacogenomics (PGx) Scope and Market Size
Pharmacogenomics (PGx) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pharmacogenomics (PGx) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Polymerase Chain Reaction (PCR)
Microarray
Sequencing
Other

Segment by Application
Cardiovascular Diseases (CVD)
Central Nervous System (CNS)
Cancer/Oncology
Infectious Diseases
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott Laboratories
Affymetrix, Inc.
Assurex Health, Inc
Astrazeneca
GeneDX
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
Pathway Genomics
Pfizer, Inc
Qiagen, Inc.
Rocheg
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
Transgenomic, Inc.

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics (PGx) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Microarray
1.2.4 Sequencing
1.2.5 Other
1.3 Market by Application
1.3.1 Global Pharmacogenomics (PGx) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Cardiovascular Diseases (CVD)
1.3.3 Central Nervous System (CNS)
1.3.4 Cancer/Oncology
1.3.5 Infectious Diseases
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Pharmacogenomics (PGx) Market Perspective (2016-2027)
2.2 Pharmacogenomics (PGx) Growth Trends by Regions
2.2.1 Pharmacogenomics (PGx) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Pharmacogenomics (PGx) Historic Market Share by Regions (2016-2021)
2.2.3 Pharmacogenomics (PGx) Forecasted Market Size by Regions (2022-2027)
2.3 Pharmacogenomics (PGx) Industry Dynamic
2.3.1 Pharmacogenomics (PGx) Market Trends
2.3.2 Pharmacogenomics (PGx) Market Drivers
2.3.3 Pharmacogenomics (PGx) Market Challenges
2.3.4 Pharmacogenomics (PGx) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics (PGx) Players by Revenue
3.1.1 Global Top Pharmacogenomics (PGx) Players by Revenue (2016-2021)
3.1.2 Global Pharmacogenomics (PGx) Revenue Market Share by Players (2016-2021)
3.2 Global Pharmacogenomics (PGx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics (PGx) Revenue
3.4 Global Pharmacogenomics (PGx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics (PGx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics (PGx) Revenue in 2020
3.5 Pharmacogenomics (PGx) Key Players Head office and Area Served
3.6 Key Players Pharmacogenomics (PGx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics (PGx) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Pharmacogenomics (PGx) Breakdown Data by Type
4.1 Global Pharmacogenomics (PGx) Historic Market Size by Type (2016-2021)
4.2 Global Pharmacogenomics (PGx) Forecasted Market Size by Type (2022-2027)

5 Pharmacogenomics (PGx) Breakdown Data by Application
5.1 Global Pharmacogenomics (PGx) Historic Market Size by Application (2016-2021)
5.2 Global Pharmacogenomics (PGx) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Pharmacogenomics (PGx) Market Size (2016-2027)
6.2 North America Pharmacogenomics (PGx) Market Size by Type
6.2.1 North America Pharmacogenomics (PGx) Market Size by Type (2016-2021)
6.2.2 North America Pharmacogenomics (PGx) Market Size by Type (2022-2027)
6.2.3 North America Pharmacogenomics (PGx) Market Size by Type (2016-2027)
6.3 North America Pharmacogenomics (PGx) Market Size by Application
6.3.1 North America Pharmacogenomics (PGx) Market Size by Application (2016-2021)
6.3.2 North America Pharmacogenomics (PGx) Market Size by Application (2022-2027)
6.3.3 North America Pharmacogenomics (PGx) Market Size by Application (2016-2027)
6.4 North America Pharmacogenomics (PGx) Market Size by Country
6.4.1 North America Pharmacogenomics (PGx) Market Size by Country (2016-2021)
6.4.2 North America Pharmacogenomics (PGx) Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Pharmacogenomics (PGx) Market Size (2016-2027)
7.2 Europe Pharmacogenomics (PGx) Market Size by Type
7.2.1 Europe Pharmacogenomics (PGx) Market Size by Type (2016-2021)
7.2.2 Europe Pharmacogenomics (PGx) Market Size by Type (2022-2027)
7.2.3 Europe Pharmacogenomics (PGx) Market Size by Type (2016-2027)
7.3 Europe Pharmacogenomics (PGx) Market Size by Application
7.3.1 Europe Pharmacogenomics (PGx) Market Size by Application (2016-2021)
7.3.2 Europe Pharmacogenomics (PGx) Market Size by Application (2022-2027)
7.3.3 Europe Pharmacogenomics (PGx) Market Size by Application (2016-2027)
7.4 Europe Pharmacogenomics (PGx) Market Size by Country
7.4.1 Europe Pharmacogenomics (PGx) Market Size by Country (2016-2021)
7.4.2 Europe Pharmacogenomics (PGx) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics (PGx) Market Size (2016-2027)
8.2 Asia-Pacific Pharmacogenomics (PGx) Market Size by Type
8.2.1 Asia-Pacific Pharmacogenomics (PGx) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Pharmacogenomics (PGx) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Pharmacogenomics (PGx) Market Size by Type (2016-2027)
8.3 Asia-Pacific Pharmacogenomics (PGx) Market Size by Application
8.3.1 Asia-Pacific Pharmacogenomics (PGx) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Pharmacogenomics (PGx) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Pharmacogenomics (PGx) Market Size by Application (2016-2027)
8.4 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region
8.4.1 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Pharmacogenomics (PGx) Market Size (2016-2027)
9.2 Latin America Pharmacogenomics (PGx) Market Size by Type
9.2.1 Latin America Pharmacogenomics (PGx) Market Size by Type (2016-2021)
9.2.2 Latin America Pharmacogenomics (PGx) Market Size by Type (2022-2027)
9.2.3 Latin America Pharmacogenomics (PGx) Market Size by Type (2016-2027)
9.3 Latin America Pharmacogenomics (PGx) Market Size by Application
9.3.1 Latin America Pharmacogenomics (PGx) Market Size by Application (2016-2021)
9.3.2 Latin America Pharmacogenomics (PGx) Market Size by Application (2022-2027)
9.3.3 Latin America Pharmacogenomics (PGx) Market Size by Application (2016-2027)
9.4 Latin America Pharmacogenomics (PGx) Market Size by Country
9.4.1 Latin America Pharmacogenomics (PGx) Market Size by Country (2016-2021)
9.4.2 Latin America Pharmacogenomics (PGx) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics (PGx) Market Size (2016-2027)
10.2 Middle East & Africa Pharmacogenomics (PGx) Market Size by Type
10.2.1 Middle East & Africa Pharmacogenomics (PGx) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Pharmacogenomics (PGx) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Pharmacogenomics (PGx) Market Size by Type (2016-2027)
10.3 Middle East & Africa Pharmacogenomics (PGx) Market Size by Application
10.3.1 Middle East & Africa Pharmacogenomics (PGx) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Pharmacogenomics (PGx) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Pharmacogenomics (PGx) Market Size by Application (2016-2027)
10.4 Middle East & Africa Pharmacogenomics (PGx) Market Size by Country
10.4.1 Middle East & Africa Pharmacogenomics (PGx) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Pharmacogenomics (PGx) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Pharmacogenomics (PGx) Introduction
11.1.4 Abbott Laboratories Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.1.5 Abbott Laboratories Recent Development
11.2 Affymetrix, Inc.
11.2.1 Affymetrix, Inc. Company Details
11.2.2 Affymetrix, Inc. Business Overview
11.2.3 Affymetrix, Inc. Pharmacogenomics (PGx) Introduction
11.2.4 Affymetrix, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.2.5 Affymetrix, Inc. Recent Development
11.3 Assurex Health, Inc
11.3.1 Assurex Health, Inc Company Details
11.3.2 Assurex Health, Inc Business Overview
11.3.3 Assurex Health, Inc Pharmacogenomics (PGx) Introduction
11.3.4 Assurex Health, Inc Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.3.5 Assurex Health, Inc Recent Development
11.4 Astrazeneca
11.4.1 Astrazeneca Company Details
11.4.2 Astrazeneca Business Overview
11.4.3 Astrazeneca Pharmacogenomics (PGx) Introduction
11.4.4 Astrazeneca Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.4.5 Astrazeneca Recent Development
11.5 GeneDX
11.5.1 GeneDX Company Details
11.5.2 GeneDX Business Overview
11.5.3 GeneDX Pharmacogenomics (PGx) Introduction
11.5.4 GeneDX Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.5.5 GeneDX Recent Development
11.6 Illumina, Inc.
11.6.1 Illumina, Inc. Company Details
11.6.2 Illumina, Inc. Business Overview
11.6.3 Illumina, Inc. Pharmacogenomics (PGx) Introduction
11.6.4 Illumina, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.6.5 Illumina, Inc. Recent Development
11.7 Laboratory Corporation of America Holdings
11.7.1 Laboratory Corporation of America Holdings Company Details
11.7.2 Laboratory Corporation of America Holdings Business Overview
11.7.3 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Introduction
11.7.4 Laboratory Corporation of America Holdings Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.7.5 Laboratory Corporation of America Holdings Recent Development
11.8 Myriad Genetics, Inc.
11.8.1 Myriad Genetics, Inc. Company Details
11.8.2 Myriad Genetics, Inc. Business Overview
11.8.3 Myriad Genetics, Inc. Pharmacogenomics (PGx) Introduction
11.8.4 Myriad Genetics, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.8.5 Myriad Genetics, Inc. Recent Development
11.9 Pathway Genomics
11.9.1 Pathway Genomics Company Details
11.9.2 Pathway Genomics Business Overview
11.9.3 Pathway Genomics Pharmacogenomics (PGx) Introduction
11.9.4 Pathway Genomics Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.9.5 Pathway Genomics Recent Development
11.10 Pfizer, Inc
11.10.1 Pfizer, Inc Company Details
11.10.2 Pfizer, Inc Business Overview
11.10.3 Pfizer, Inc Pharmacogenomics (PGx) Introduction
11.10.4 Pfizer, Inc Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.10.5 Pfizer, Inc Recent Development
11.11 Qiagen, Inc.
11.11.1 Qiagen, Inc. Company Details
11.11.2 Qiagen, Inc. Business Overview
11.11.3 Qiagen, Inc. Pharmacogenomics (PGx) Introduction
11.11.4 Qiagen, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.11.5 Qiagen, Inc. Recent Development
11.12 Rocheg
11.12.1 Rocheg Company Details
11.12.2 Rocheg Business Overview
11.12.3 Rocheg Pharmacogenomics (PGx) Introduction
11.12.4 Rocheg Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.12.5 Rocheg Recent Development
11.13 Teva Pharmaceutical Industries Ltd.
11.13.1 Teva Pharmaceutical Industries Ltd. Company Details
11.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.13.3 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Introduction
11.13.4 Teva Pharmaceutical Industries Ltd. Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.13.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.14 Thermo Fisher Scientific
11.14.1 Thermo Fisher Scientific Company Details
11.14.2 Thermo Fisher Scientific Business Overview
11.14.3 Thermo Fisher Scientific Pharmacogenomics (PGx) Introduction
11.14.4 Thermo Fisher Scientific Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.14.5 Thermo Fisher Scientific Recent Development
11.15 Transgenomic, Inc.
11.15.1 Transgenomic, Inc. Company Details
11.15.2 Transgenomic, Inc. Business Overview
11.15.3 Transgenomic, Inc. Pharmacogenomics (PGx) Introduction
11.15.4 Transgenomic, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021)
11.15.5 Transgenomic, Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Pharmacogenomics (PGx) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of Microarray
Table 4. Key Players of Sequencing
Table 5. Key Players of Other
Table 6. Global Pharmacogenomics (PGx) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Pharmacogenomics (PGx) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Pharmacogenomics (PGx) Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Pharmacogenomics (PGx) Market Share by Regions (2016-2021)
Table 10. Global Pharmacogenomics (PGx) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Pharmacogenomics (PGx) Market Share by Regions (2022-2027)
Table 12. Pharmacogenomics (PGx) Market Trends
Table 13. Pharmacogenomics (PGx) Market Drivers
Table 14. Pharmacogenomics (PGx) Market Challenges
Table 15. Pharmacogenomics (PGx) Market Restraints
Table 16. Global Pharmacogenomics (PGx) Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Pharmacogenomics (PGx) Market Share by Players (2016-2021)
Table 18. Global Top Pharmacogenomics (PGx) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pharmacogenomics (PGx) as of 2020)
Table 19. Ranking of Global Top Pharmacogenomics (PGx) Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Pharmacogenomics (PGx) Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Pharmacogenomics (PGx) Product Solution and Service
Table 23. Date of Enter into Pharmacogenomics (PGx) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Pharmacogenomics (PGx) Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Pharmacogenomics (PGx) Revenue Market Share by Type (2016-2021)
Table 27. Global Pharmacogenomics (PGx) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Pharmacogenomics (PGx) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Pharmacogenomics (PGx) Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Pharmacogenomics (PGx) Revenue Market Share by Application (2016-2021)
Table 31. Global Pharmacogenomics (PGx) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Pharmacogenomics (PGx) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Pharmacogenomics (PGx) Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Pharmacogenomics (PGx) Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Pharmacogenomics (PGx) Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Pharmacogenomics (PGx) Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Pharmacogenomics (PGx) Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Pharmacogenomics (PGx) Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Pharmacogenomics (PGx) Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Pharmacogenomics (PGx) Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Pharmacogenomics (PGx) Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Pharmacogenomics (PGx) Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Pharmacogenomics (PGx) Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Pharmacogenomics (PGx) Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Pharmacogenomics (PGx) Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Pharmacogenomics (PGx) Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Pharmacogenomics (PGx) Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Pharmacogenomics (PGx) Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Pharmacogenomics (PGx) Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Pharmacogenomics (PGx) Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Pharmacogenomics (PGx) Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Pharmacogenomics (PGx) Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Pharmacogenomics (PGx) Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Pharmacogenomics (PGx) Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Pharmacogenomics (PGx) Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Pharmacogenomics (PGx) Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Pharmacogenomics (PGx) Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Pharmacogenomics (PGx) Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Pharmacogenomics (PGx) Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Pharmacogenomics (PGx) Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Pharmacogenomics (PGx) Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Pharmacogenomics (PGx) Market Size by Country (2022-2027) & (US$ Million)
Table 63. Abbott Laboratories Company Details
Table 64. Abbott Laboratories Business Overview
Table 65. Abbott Laboratories Pharmacogenomics (PGx) Product
Table 66. Abbott Laboratories Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 67. Abbott Laboratories Recent Development
Table 68. Affymetrix, Inc. Company Details
Table 69. Affymetrix, Inc. Business Overview
Table 70. Affymetrix, Inc. Pharmacogenomics (PGx) Product
Table 71. Affymetrix, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 72. Affymetrix, Inc. Recent Development
Table 73. Assurex Health, Inc Company Details
Table 74. Assurex Health, Inc Business Overview
Table 75. Assurex Health, Inc Pharmacogenomics (PGx) Product
Table 76. Assurex Health, Inc Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 77. Assurex Health, Inc Recent Development
Table 78. Astrazeneca Company Details
Table 79. Astrazeneca Business Overview
Table 80. Astrazeneca Pharmacogenomics (PGx) Product
Table 81. Astrazeneca Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 82. Astrazeneca Recent Development
Table 83. GeneDX Company Details
Table 84. GeneDX Business Overview
Table 85. GeneDX Pharmacogenomics (PGx) Product
Table 86. GeneDX Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 87. GeneDX Recent Development
Table 88. Illumina, Inc. Company Details
Table 89. Illumina, Inc. Business Overview
Table 90. Illumina, Inc. Pharmacogenomics (PGx) Product
Table 91. Illumina, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 92. Illumina, Inc. Recent Development
Table 93. Laboratory Corporation of America Holdings Company Details
Table 94. Laboratory Corporation of America Holdings Business Overview
Table 95. Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Product
Table 96. Laboratory Corporation of America Holdings Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 97. Laboratory Corporation of America Holdings Recent Development
Table 98. Myriad Genetics, Inc. Company Details
Table 99. Myriad Genetics, Inc. Business Overview
Table 100. Myriad Genetics, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 101. Myriad Genetics, Inc. Recent Development
Table 102. Pathway Genomics Company Details
Table 103. Pathway Genomics Business Overview
Table 104. Pathway Genomics Pharmacogenomics (PGx) Product
Table 105. Pathway Genomics Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 106. Pathway Genomics Recent Development
Table 107. Pfizer, Inc Company Details
Table 108. Pfizer, Inc Business Overview
Table 109. Pfizer, Inc Pharmacogenomics (PGx) Product
Table 110. Pfizer, Inc Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 111. Pfizer, Inc Recent Development
Table 112. Qiagen, Inc. Company Details
Table 113. Qiagen, Inc. Business Overview
Table 114. Qiagen, Inc. Pharmacogenomics (PGx) Product
Table 115. Qiagen, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 116. Qiagen, Inc. Recent Development
Table 117. Rocheg Company Details
Table 118. Rocheg Business Overview
Table 119. Rocheg Pharmacogenomics (PGx) Product
Table 120. Rocheg Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 121. Rocheg Recent Development
Table 122. Teva Pharmaceutical Industries Ltd. Company Details
Table 123. Teva Pharmaceutical Industries Ltd. Business Overview
Table 124. Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Product
Table 125. Teva Pharmaceutical Industries Ltd. Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 126. Teva Pharmaceutical Industries Ltd. Recent Development
Table 127. Thermo Fisher Scientific Company Details
Table 128. Thermo Fisher Scientific Business Overview
Table 129. Thermo Fisher Scientific Pharmacogenomics (PGx) Product
Table 130. Thermo Fisher Scientific Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 131. Thermo Fisher Scientific Recent Development
Table 132. Transgenomic, Inc. Company Details
Table 133. Transgenomic, Inc. Business Overview
Table 134. Transgenomic, Inc. Pharmacogenomics (PGx) Product
Table 135. Transgenomic, Inc. Revenue in Pharmacogenomics (PGx) Business (2016-2021) & (US$ Million)
Table 136. Transgenomic, Inc. Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pharmacogenomics (PGx) Market Share by Type: 2020 VS 2027
Figure 2. Polymerase Chain Reaction (PCR) Features
Figure 3. Microarray Features
Figure 4. Sequencing Features
Figure 5. Other Features
Figure 6. Global Pharmacogenomics (PGx) Market Share by Application: 2020 VS 2027
Figure 7. Cardiovascular Diseases (CVD) Case Studies
Figure 8. Central Nervous System (CNS) Case Studies
Figure 9. Cancer/Oncology Case Studies
Figure 10. Infectious Diseases Case Studies
Figure 11. Other Case Studies
Figure 12. Pharmacogenomics (PGx) Report Years Considered
Figure 13. Global Pharmacogenomics (PGx) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Pharmacogenomics (PGx) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Pharmacogenomics (PGx) Market Share by Regions: 2020 VS 2027
Figure 16. Global Pharmacogenomics (PGx) Market Share by Regions (2022-2027)
Figure 17. Global Pharmacogenomics (PGx) Market Share by Players in 2020
Figure 18. Global Top Pharmacogenomics (PGx) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pharmacogenomics (PGx) as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Pharmacogenomics (PGx) Revenue in 2020
Figure 20. Global Pharmacogenomics (PGx) Revenue Market Share by Type (2016-2021)
Figure 21. Global Pharmacogenomics (PGx) Revenue Market Share by Type (2022-2027)
Figure 22. North America Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Pharmacogenomics (PGx) Market Share by Type (2016-2027)
Figure 24. North America Pharmacogenomics (PGx) Market Share by Application (2016-2027)
Figure 25. North America Pharmacogenomics (PGx) Market Share by Country (2016-2027)
Figure 26. United States Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Pharmacogenomics (PGx) Market Share by Type (2016-2027)
Figure 30. Europe Pharmacogenomics (PGx) Market Share by Application (2016-2027)
Figure 31. Europe Pharmacogenomics (PGx) Market Share by Country (2016-2027)
Figure 32. Germany Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Pharmacogenomics (PGx) Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Pharmacogenomics (PGx) Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Pharmacogenomics (PGx) Market Share by Region (2016-2027)
Figure 42. China Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Pharmacogenomics (PGx) Market Share by Type (2016-2027)
Figure 50. Latin America Pharmacogenomics (PGx) Market Share by Application (2016-2027)
Figure 51. Latin America Pharmacogenomics (PGx) Market Share by Country (2016-2027)
Figure 52. Mexico Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Pharmacogenomics (PGx) Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Pharmacogenomics (PGx) Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Pharmacogenomics (PGx) Market Share by Country (2016-2027)
Figure 58. Turkey Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Pharmacogenomics (PGx) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Abbott Laboratories Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 62. Affymetrix, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 63. Assurex Health, Inc Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 64. Astrazeneca Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 65. GeneDX Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 66. Illumina, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 67. Laboratory Corporation of America Holdings Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 68. Myriad Genetics, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 69. Pathway Genomics Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 70. Pfizer, Inc Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 71. Qiagen, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 72. Rocheg Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 73. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 74. Thermo Fisher Scientific Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 75. Transgenomic, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2016-2021)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed